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Background: Adult-onset growth hormone (GH) deficiency (AGHD) is related with
alterations in body composition, increased abdominal and visceral adiposity, adverse
change in lipid and carbohydrate metabolism, and reduction of bone mineral density
(BMD). Aim: To compare body composition and biochemical/hormonal data among
adult patients with AGHD referring to a single endocrinological center and grouped
according to r-hGH therapy. Methods: The Manage Growth Hormone Deficiency
Study (MAGHD) is a prospective, single-center trial aiming to improve AGHD
management through a smartphone app (MAGHD App: Manage AGHD) integrated
with a software framework able to merge several kind of patients’ daily data with
clinical data collected in institutional databases. Up-to-now, a total of 74 subjects (26
Female, 48 Male, mean age: 56.6+14.8 years) with AGHD, fulfilling the inclusion
criteria, were enrolled in the study. According to r-hGH therapy, they were divided in 3
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groups: patients on long-term r-hGH therapy (Group 1, n=33), patients previously
treated with r-hGH, who had stopped the therapy at any time (Group 2, n=18),
patients never treated (Group 3, n=23). Each patient has completed the baseline visit,
including biochemical and hormonal measurements and data on BMD and body
composition obtained by DXA. The nonparametric Kruskal-Wallis test was used for
comparison among 3 groups and data are expressed as median. Results: Mean
duration of AGHD disease of the entire cohort was 121.2+105.8 months; it was lower in
Group 3 compared to both Group 1 and 2 (p<0.05). Waist circumference (Group 1 95
cm; Group 2 96,5 cm; Group 3 109 cm) and trunk fat mass (Group 1 539 g; Group 2 525
g; Group 3 595 g) were significantly higher in Group 3 compared to both Group 2 and 1
(p<0.05). Serum insulin, total fat mass, and total body fat (%) were significantly
higher in Group 3 than Group 1 (p<0.05). IGF-1 and IGFBP3 were significantly higher
in Group 1 compared to both Group 2 and 3 (p<0.0001). BMD, circulating lipids, and
fasting glucose did not di!er among the 3 groups. Conclusions: r-hGH therapy seems
to confer a long-lasting beneficial e!ect on body fat, especially trunk fat even after its
discontinuation in AGHD patients, but not on metabolic parameters.
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